This saves patients hours annually, time they can spend with family, at work, or relaxing, while also offering major ...

Participants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

The UK's National Health Service has introduced a quick injection method for administering the cancer drug Nivolumab, significantly reducing treatment time and hospital stays.

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

The complete remission of a testicular cancer patient receiving Mink Therapeutics Inc.’s allogeneic, off-the-shelf invariant natural killer T-cell therapy Agent-797 with nivolumab drove the company’s ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

England's National Health Service will soon offer nivolumab as a quick injection for cancer patients. This new method cuts ...

Most patients with advanced melanoma treated with pre-surgical immunotherapy remained alive and free of disease four years post-treatment.

Gynecological clear cell cancers (CCCs), very aggressive forms of ovarian and endometrial malignancies, respond poorly to chemotherapy.  The low respo | Cancer ...